Correspondence 0001193125-23-009277 from Compass Therapeutics, Inc. (CMPX) (CIK 0001738021) (CMPX)
Compass Therapeutics, Inc. (CMPX) (CIK 0001738021)
Date: Jan. 17, 2023 · CIK: 0001738021 · Accession: 0001193125-23-009277
AI Filing Summary & Sentiment
File numbers found in text: 333-268652
Letter
COMPASS THERAPEUTICS, INC.
80 Guest Street
Suite
Boston, Massachusetts 02135
January 17, 2023
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Re: Withdrawal of Acceleration Request—Compass Therapeutics, Inc.: Registration Statement on
Form S-3 filed December 2, 2022 (File No. 333-268652)
Ladies and Gentlemen:
Reference is made to our letter, filed as correspondence via EDGAR on January 13, 2023, in which we requested the acceleration of the effective date of the above-referenced Registration Statement for Tuesday, January 17, 2023, at 4:00 p.m. Eastern Time, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.
If you have any questions regarding this request for withdrawal, please contact James Xu of Goodwin Procter LLP at (650) 752-3355.
Sincerely,
Compass Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP COMPASS THERAPEUTICS, INC. 80 Guest Street Suite 601 Boston, Massachusetts 02135 January 17, 2023 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Re: Withdrawal of Acceleration Request—Compass Therapeutics, Inc.: Registration Statement on Form S-3 filed December 2, 2022 (File No. 333-268652) Ladies and Gentlemen: Reference is made to our letter, filed as correspondence via EDGAR on January 13, 2023, in which we requested the acceleration of the effective date of the above-referenced Registration Statement for Tuesday, January 17, 2023, at 4:00 p.m. Eastern Time, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date. If you have any questions regarding this request for withdrawal, please contact James Xu of Goodwin Procter LLP at (650) 752-3355. Sincerely, Compass Therapeutics, Inc. /s/ Vered Bisker-Leib Vered Bisker-Leib President and Chief Operating Officer cc: Vered Bisker-Leib, Compass Therapeutics, Inc. Jonathan Anderman, Compass Therapeutics, Inc. Richard Hoffman, Esq., Goodwin Procter LLP James Xu, Esq., Goodwin Procter LLP